Ofatumumab: Difference between revisions
m Protected "Ofatumumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 32: | Line 32: | ||
{{Humanmonoclonals}} | {{Humanmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 14:28, 20 August 2012
WikiDoc Resources for Ofatumumab |
Articles |
---|
Most recent articles on Ofatumumab |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Ofatumumab at Clinical Trials.gov Clinical Trials on Ofatumumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Ofatumumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Ofatumumab Discussion groups on Ofatumumab Patient Handouts on Ofatumumab Directions to Hospitals Treating Ofatumumab Risk calculators and risk factors for Ofatumumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Ofatumumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Ofatumumab is a human monoclonal antibody and which it is used to treat cancer. It is currently in a phase 3 dosage trial to assess it's effect in patients with relapsed follicular non-Hodgkin's lymphoma.